Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study
Pediatric Blood & Cancer2016Vol. 63(8), pp. 1407–1413
Citations Over TimeTop 10% of 2016 papers
Cindy Neunert, Jenny M. Despotovic, Kristina M. Haley, Michele P. Lambert, Kerri Nottage, Kristin A. Shimano, Carolyn M. Bennett, Robert J. Klaassen, Kimo C. Stine, Alexis A. Thompson, Yves Pastore, Travis Brown, Peter W. Forbes, Rachael F. Grace
Abstract
Our results demonstrate that TPO-RA agents are being used in children with ITP of varying duration and severity. The response was similar to clinical trials, but the sustainability of response varied. Future studies need to focus on the ideal timing and rationale for these medications in pediatric patients.
Related Papers
- → Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia(2011)124 cited
- → Thrombocytopenia in Patients With Myelodysplastic Syndromes(2010)38 cited
- → Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?(2016)1 cited
- → Clinical Applications and Advances of Thrombopoietin Receptor Agonist(2014)
- → Role of thrombopoietin stimulating agents (Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE(2021)